A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).

Clinical trial NCT05513950 · COMPLETED

Trial details

NCT number: NCT05513950
Sponsor: Chiesi Farmaceutici S.p.A.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis

Start date: 2023-01-25
Primary completion: 2024-06-17
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.